Evidence map›Paper›PMID 35583725›Full record

ArticleInternational journal of hematology2022

Higher incidence of thrombocytopenia during obinutuzumab plus bendamustine therapy for untreated follicular lymphoma: a retrospective analysis by the Okayama Hematology Study Group.

Yuki Fujiwara, Tomohiro Urata, Daigo Niiya, Tomofumi Yano, Yuichiro Nawa, Isao Yoshida, Toshi Imai, Kazutaka Sunami, Soichiro Fujii, Daisuke Ennishi and 2 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yuki Fujiwara *Department of Hematology and Oncology, Japanese Red Cross Society Himeji Hospital, Himeji, Japan.
Tomohiro Urata *Department of Hematology and Oncology, Okayama University Hospital, 2-5-1, Shikata-cho, Kita-ku, Okayama, Japan.
Daigo NiiyaDepartment of Hematology, Okayama City Hospital, Okayama, Japan.
Tomofumi YanoDepartment of Internal Medicine, Okayama Rosai Hospital, Okayama, Japan.
Yuichiro NawaDivision of Hematology, Ehime Prefectural Central Hospital, Matsuyama, Japan.
Isao YoshidaDepartment of Hematologic Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.
Toshi ImaiDepartment of Hematology and Blood Transfusion, Kochi Health Sciences Center, Kochi, Japan.
Kazutaka SunamiDepartment of Hematology, National Hospital Organization Okayama Medical Center, Okayama, Japan.
Soichiro FujiiDepartment of Hematology, Japanese Red Cross Okayama Hospital, Okayama, Japan.
Daisuke EnnishiDepartment of Hematology and Oncology, Okayama University Hospital, 2-5-1, Shikata-cho, Kita-ku, Okayama, Japan. daisukeennishi@okayama-u.ac.jp.
Yoshinobu MaedaDepartment of Hematology and Oncology, Okayama University Hospital, 2-5-1, Shikata-cho, Kita-ku, Okayama, Japan.
Yasushi HiramatsuDepartment of Hematology and Oncology, Japanese Red Cross Society Himeji Hospital, Himeji, Japan. hirayasu200582@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Progression-free survival in patients with untreated follicular lymphoma (FL) has significantly improved with obinutuzumab plus chemotherapy followed by obinutuzumab maintenance, compared with rituximab plus chemotherapy. However, the survival outcome and adverse event profile in Japanese FL patients treated with obinutuzumab plus bendamustine (GB) therapy are not well investigated. Recently, we encountered some cases of grade 3-4 thrombocytopenia during GB therapy in patients with FL. This retrospective multicenter survey aimed to identify the characteristics of patients who received GB therapy and developed thrombocytopenia. A total of 54 patients with FL treated by GB therapy between August 2018 and December 2020 were investigated. After a median follow-up of 12.6 months, thrombocytopenia of any grade was observed in 48 (88.9%) patients, including 9 (16.7%) patients with grade 3-4 thrombocytopenia. Notably, although eight of nine patients with grade 3-4 thrombocytopenia were female, no patient characteristics (including gender) were significantly associated with grade 3-4 thrombocytopenia. Importantly, grade 3-4 thrombocytopenia frequently occurred in the first GB therapy cycle, which suggests that platelet count should be monitored carefully in patients who have just started GB therapy.

Indexed as

HematologyLeukopeniaLymphoma, FollicularThrombocytopeniaAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBendamustine HydrochlorideFemaleHumansIncidenceMaleRetrospective StudiesRituximabAntibodies, Monoclonal, HumanizedBendamustine HydrochlorideobinutuzumabRituximabBendamustineFollicular lymphomaObinutuzumabThrombocytopenia

Identifiers

PMID35583725

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.